Abecma (idecabtagene vicleucel)

pCPA File Number: 21655
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Sponsor/Manufacturer:
Celgene Inc.
CADTH Project Number:
PG0240-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable